The Trump Administration will promote legislation to remove the cap on prescription drug inflation rebates in Medicaid to enable rebates of more than 100% of a drug's price, HHS Secretary Alex Azar told a recent policy conference at the American Enterprise Institute.
Medicaid Reform: Trump Administration Pursuing Rebates Over 100%
States might also be able to test closed formularies in Medicaid as Trump Administration seeks stronger disincentives for price increases.
More from Pricing Debate
• By
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
• By
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.
• By
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.